Bloomberg Talks Novo's Martin Holst Lange Talks New Weight Loss Shot
Feb 23, 2026
Martin Holst Lange, Chief Scientific Officer at Novo Nordisk, leads scientific development for obesity and metabolic therapies. He discusses why recent CagriSema trial results need context and how titration and higher-dose studies may change outcomes. He also outlines Novo Nordisk’s broader pipeline strategy and why the company chose a different scientific route than some competitors.
AI Snips
Chapters
Transcript
Episode notes
CagriSema Achieved Strong 23 Percent Weight Loss
- CagriSema produced substantial weight loss of about 23% in the reported trial.
- Martin Holst Lange emphasized this is consistent with prior results and ranks among top market outcomes despite falling short of Lilly's readout.
Titration Strategy Can Change Drug Efficacy Outcomes
- Novo says the observed 23% may underrepresent CagriSema's full potential without optimized titration.
- Holst Lange noted earlier studies showed titration algorithms are critical to unlock the combination's true efficacy.
Lilly's 25 Percent Result Was Unusually Strong
- Lilly's 25% result stands out as unusually high in head‑to‑head comparison.
- Holst Lange called that 25% surprising and said it 'stands alone', reinforcing why Novo is studying adjustable approaches.